Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Inês Pires da Silva(The University of Sydney), Tasnia Ahmed(The University of Sydney), Irene L. M. Reijers(The Netherlands Cancer Institute), Alison M. Weppler(The University of Melbourne), Allison Betof Warner(Memorial Sloan Kettering Cancer Center), James R. Patrinely(Vanderbilt University Medical Center), Patricio Serra-Bellver(The Christie NHS Foundation Trust), Clara Allayous(Université Paris Cité), Joanna Mangana(University Hospital of Zurich), Khang Nguyen(Westmead Hospital), Lisa Zimmer(University of Duisburg-Essen), Claudia Trojaniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dan Stout(Monash University), Megan Lyle(James Cook University), Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), Camille L. Gérard(University of Lausanne), Olivier Michielin(University of Lausanne), Andrew Haydon(Monash University), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Matteo S. Carlino(Melanoma Institute Australia), Célèste Lebbé(Assistance Publique – Hôpitaux de Paris), Paul Lorigan(Cancer Research UK Manchester Institute), Douglas B. Johnson(Vanderbilt University Medical Center), Shahneen Sandhu(The University of Melbourne), Serigne Lo(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Alexander M. Menzies(Royal North Shore Hospital), Georgina V. Long(Mater Health Services)
Cited by 211
Abstract
Related Papers
No related papers found
Powered by citation graph analysis